| Product Name | Mouse anti rat Osteopontin Antibody (AR.1C) (01-20002) |
|---|---|
| Description | Anti-Osteopontin Antibody (01-20002). Osteopontin (OPN) is a secreted glycoprotein that was originally isolated from bone. At present, it is known as a highly acidic calcium-binding glycosylated phosphoprotein secreted by many cell types, including osteoblasts, kidney tubule cells, macrophages, activated T cells, and vascular smooth muscle cells. OPN's molecular weights have been reported in the range of 66 kDa to 44 kDa depending on glycosylation and phosphorylation. One important feature of OPN is that it contains an Arg-Gly-Asp (RGD) amino acid sequence. This motif is present in fibronectin, vitronectin and a variety of otherextra cellular proteins that bind members of the integrin family of cell surfacereceptors such as avb3. Another important of OPN is is the presence of various molecular forms in vivo dueto differential RNA splicing, glycosylation, phosphorylation, sulfation, and susceptibility to proteases. Both OPN and thrombin are likely to be localizedtogether at the site of injury, in- flammation, and angiogenesis and in tumor tissues. Osteopontin is susceptible to proteolytic fragmentation, and this process may have physiologic importance. A report demonstrated that thrombin treatment enhanced OPN cell adhesive activity, suggesting that cleavage of OPN by thrombin exposes acryptic adhesive sequence. More recently, it was shown that an amino-terminal OPN fragment contains a cryptic binding site that can be recognized by a9b1 integrin.Furthermore, OPN contains multiple cell binding sites and interacts with various receptors; these interactions may have distinct functional. Mouse monoclonal Antibody to Osteopontin |
| Clone | AR.1C |
| Immunogen | Osteopontin from rat |
| Isotype | Mouse IgG1 |
| Specificity | Rat Osteopontin |
| Reactivity | Rat |
| Applications | ELISA, IHC, WB, Dot Blot |
| Form | Stabilized serum containing 0.1% sodium azide |
| Storage | 2-8C for immediate use, or at -20C (aliquot) |
| Background |
Osteopontin (OPN) is a secreted glycoprotein that was originally isolated from bone. At present, it is known as a highly acidic calcium-binding glycosylated phosphoprotein secreted by many cell types, including osteoblasts, kidney tubule cells, macrophages, activated T cells, and vascular smooth muscle cells. OPN's molecular weights have been reported in the range of 66 kDa to 44 kDa depending on glycosylation and phosphorylation. One important feature of OPN is that it contains an Arg-Gly-Asp (RGD) amino acid sequence. This motif is present in fibronectin, vitronectin and a variety of otherextra cellular proteins that bind members of the integrin family of cell surfacereceptors such as avb3. Another important of OPN is is the presence of various molecular forms in vivo dueto differential RNA splicing, glycosylation, phosphorylation, sulfation, and susceptibility to proteases. Both OPN and thrombin are likely to be localizedtogether at the site of injury, in- flammation, and angiogenesis and in tumor tissues. Osteopontin is susceptible to proteolytic fragmentation, and this process may have physiologic importance. A report demonstrated that thrombin treatment enhanced OPN cell adhesive activity, suggesting that cleavage of OPN by thrombin exposes acryptic adhesive sequence. More recently, it was shown that an amino-terminal OPN fragment contains a cryptic binding site that can be recognized by a9b1 integrin.Furthermore, OPN contains multiple cell binding sites and interacts with various receptors; these interactions may have distinct functional. |
| Supplier | ARP |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
